Astellas Pharma is on track to purchase Ocata Therapeutics (formerly Advanced Cell Technology). This has stirred a lot of strong feelings amongst investors in Ocata. (Update, now almost 5 years later, the Ocata vision program is still not going full steam ahead at its new owner it seems). I’ve also been wondering what exactly is Astellas Pharma? Astellas is a giant compared to Ocata with reportedly $11 billion USD in revenue and $1.3 billion in profit just in the year 2013 alone. While Ocata …Read More
With more than 4,142 votes cast, the readers of this blog have chosen the top 12 finalists for the Stem Cell Person of the Year Award for 2014 from the 27 nominees. You can see the final vote tallies at left. The votes came from more than 50 countries with some interesting geographic patterns (I may do a post on that as a follow up). I’ve pasted the brief bios of the twelve finalists below at the end of this post. Now comes the …Read More
Update: here is a link to the Ocata website. The start of a new era for what was formerly ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently did a notable 100:1 reverse split on its stock, opening it up to a whole new group of investors. The company has also settled some previously lingering litigation and gotten new some …Read More
Before I did the #icebucketchallenge, I challenged the leader of Advanced Cell Technology (ACT), Dr. Bob Lanza, to do the Ice Bucket Challenge. He did it and leading up to it he provided a quite articulate message for context (see video below). Bob is one very cool guy even without ice water. The purpose of the Ice Bucket Challenge is to raise money for ALS research. Bob nominated ACT scientists Irina Klimanskaya, Shi-Jiang (John) Lu, and Erin Kimbrel to go next.
What does the future hold for CIRM? I asked former CIRM Board Chair and Prop 71 leader, Robert Klein, about that and more in the interview below. He also says some particularly exciting clinical trial and other developments in the stem cell field are coming soon. What got you excited for the very first time about stem cells & regenerative medicine? Klein: In 2002, I was talking to the Director of the NIDDK, the source of the NIH funding on Diabetes Research. My son, …Read More
It has been a rollercoaster few months between the anti-hESC court cases as well as Geron and Advanced Cell Technology (ACT) receiving the OK from the FDA to proceed with initial clinical trials of stem cell treatments. It’s OK to be excited about the clinical trials and I for one am, but we have to avoid getting ahead of ourselves or having unrealistic expectations moving forward. So let’s take a breather and do some analysis of where we are and the road ahead. As …Read More